Mercedes Salgado Fernández-rekin lankidetzan egindako argitalpenak (7)

2024

  1. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

2022

  1. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

    British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880

  2. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

2020

  1. Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer: The avamet study

    Cancers, Vol. 12, Núm. 8, pp. 1-12

2018

  1. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

    Oncologist, Vol. 23, Núm. 11, pp. 1271-e128

2011

  1. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

    Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 862-868